MOHCCN Gold Cohort - Pan-Canadian Projects
The Marathon of Hope Cancer Centres Network is happy to introduce its Pan-Canadian Projects program, which unites researchers and clinicians from multiple provinces to work on projects that accelerate precision medicine for cancer in Canada.
In total, the Network will fund 20 groups through this initiative, representing a multi-million-dollar investment over the next three years that will contribute roughly 6,000 cases to the MOHCCN Gold Cohort, the largest and most complete cancer case resource in Canada.
“Until now, the bulk of our investment has supported projects within specific geographic regions, helping to create synergies within those regions and establishing the policy and technological framework needed to generate data nationally according to Network standards,” says Dr. André Veillette, executive director of the MOHCCN. “Now that these synergies exist, we are expanding our investment to projects that unite these regions, integrating researchers and clinicians in new and exciting ways.”
“This is where we will see the true impact of the Network on the Canadian cancer research and care landscape, which is why we are extremely excited to make this announcement.”
The 20 groups that will eventually make up the MOHCCN Pan-Canadian Projects were selected after a two-year process that began with a call for White Papers in November 2021 (See below).
After an administrative review from network staff, White Paper authors were contacted for their authorization to share their proposals with members of the MOHCCN Scientific Questions Working Group (SQWG) and collaborators.
The SQWG reviewed the White Papers and identified four themes emerging from the proposals that would be the basis for future projects. These themes – (i) mechanisms of drug resistance, (ii) dynamic biomarkers, (iii) prospective treatment assignment based on molecular/immune characterization and (iv) understanding cancer biology of rare and understudied cancer subtypes – along with a review criterion for a Request for Applications, were then endorsed by MOHCCN Network Council, and a request for applications was sent out. Out of the 35 applications received, 20 groups were selected to receive funding after undergoing peer review.
Pan-Canadian projects program
THIS FUNDING OPPORTUNITY IS NOW CLOSED.
The purpose of this call for white papers is to identify important questions / problems in treating Canadian cancer patients using precision medicine approaches across multiple centres that can be addressed over a three to five year time period.
Download the MOHCCN White Paper FAQ, here.
CALL FOR WHITE PAPERS
Context
The Marathon of Hope Cancer Centres Network (‘MOHCCN’) is an exciting new program managed by the Terry Fox Research Institute (‘TFRI’) with support from the federal government. The MOHCCN’s mission is to bring together leading cancer centres across Canada to collaborate on precision medicine to benefit cancer patients and drive innovation.
Inspired by Terry Fox’s courage and dedication through his 1980 Marathon of Hope, for our initial program, the MOHCCN will generate and share molecular, clinical, and health outcomes data on Canadian cancer patients. The MOHCCN will operate on a partnership model, requiring investments and matching cash contributions to be made by all partners.
It is envisioned that the MOHCCN will: (i) unite cancer centres around a national cancer strategy in precision medicine by embedding research and innovation into the cancer clinic, (ii) share knowledge and resources to impact the health outcomes of patients, (iii) align investments of foundations and the pharmaceutical sector to match the federal investment to steer activities to benefit all Canadians, and (iv) position Canada as a global leader in cancer research.
Our initial program will create a shareable databank of 15,000 Canadian cancer cases focused on four key scientific questions.
- Addressing determinants of treatment failure of immunotherapy/precision cancer medicine.
- Investigating temporal and spatial heterogeneity of tumours.
- Evaluating the clinical validity and utility of genomics for real-time clinical decision making.
- Discovering the cancer biology and genomics of rare subtypes.
Evaluation
After an administrative review from TFRI Staff, White Papers authors were contacted for their authorization to share their proposals with the Scientific Questions Working Group (SQWG) and collaborators.
The SQWG reviewed the White Papers with the mandate to identify up to 5 themes along with the development of review criteria for a Request for Applications.
The four emerging themes recommended and that have been endorsed through the governance structure by MOHCCN Network Council are:
Theme No. | Theme | Example of Enablers |
1 | Mechanisms of drug resistance (targeted and immune therapy) | Multi-omic biomarkers, profiling of immune cells and characterization of tumour microenvironment, PDX, etc |
2 | Dynamic biomarkers, including minimally invasive testing, to evaluate disease kinetics and intratumoral heterogeneity | ctDNA assays, radiomics, multi-omic circulating biomarkers, etc |
3 | Prospective treatment assignment based on molecular/immune characterization | Precision oncology clinical trials, PDX/PDO to predict drug response/resistance, multi-omic correlative studies, etc |
4 | Understanding cancer biology of rare and understudies cancer subtypes | multi-omic evaluations |
Pan-Canadian Projects Request for Applications Development Process
- November 1, 2021: deadline for expression of interest (White Paper proposals)
- July 15, 2022: SQWG committee discussion and recommendations.
- October 6th, 2022: Network Council endorsed the SQWG recommendations and TFRI issued a Request for Applications (RFA) with funding starting in the Fiscal Year 2023-2024.
- October 13th, 2022: MOHCCN Think Tank meeting, the White Paper proposals were presented in a rapid-fire format to the broader MOHCCN community.
- December 9, 2022: Pan-Canadian Applications deadline.
Application submissions
The application submission deadline is December 9, 2022, at 5 pm PST. Applicants must submit the Full Application electronically before the deadline to the email address iserrano@tfri.ca.
The electronic document attached to the email must be either (1) a PDF formatted file, or (2) a Microsoft Word document (docx format). (3) The excel file – budget template, can be converted and combined to the PDF or sent separately as xls format.
Naming of Electronic Files: 2022 TFRI MOHCCN Pan-Can Project FULL APPLICATION –LAST NAME, First Name-Lead Site.docx’
Next Steps
A panel review will be completed. The awardees will be notified in March with a projected start of the funding on April 1st, 2023.
If you need further information or have other questions, please feel free to contact TFRI at iserrano@tfri.ca.
Related News
-
MOHCCN Pan-Canadian Projects underway with announcement of first grant recipients
In total, the Network will fund 20 such groups, representing a multi-million-dollar investment over the next three years that will contribute roughly 6,000 cases to the MOHCCN Gold Cohort, the largest... -
MOHCCN Update: 2024 is off to a great start for our Network!
A note from Dr. André Veillette, Executive Director of the MOHCCN "As you read this newsletter, you will see that the Network continues to build momentum, which is why I am convinced that – thanks to your efforts – 2024 will continue to bring growth for all of us," ... -
MOHCCN announces second group of projects to receive funding through the Pan-Canadian Projects program
The Marathon of Hope Cancer Centres Network is happy to introduce the second group of projects to receive funding through its newly created Pan-Canadian Projects program. This program, which expands o... -
Marathon of Hope Cancer Centres Network tackles rare cancers in its Roadmap to Cure Cancer
Two multi-disciplinary research teams will come together for the first time to tackle two forms of rare cancer thanks to new funding from the Marathon of Hope Cancer Centres Network. Two multi-disciplinary research teams will come together for the first time to tackle two forms of rare cancer thanks to new funding from the Marathon of Hope Cancer Centres Network. -
Four new pan-Canadian research teams join the Team Canada of Cancer Research
Today’s announcement raises the number of announced projects funded through this program to 12. In total, the Network will fund 20 such groups, representing a multi-million-dollar investment over the ... -
RI-MUHC researchers work to accelerate precision medicine for cancer in Canada [External media]
The Marathon of Hope Cancer Centres Network (MOHCCN) announced this week that four new research teams will receive funding through its Pan-Canadian Projects program, which unites researchers and clini... -
Marathon of Hope Cancer Centres Network and Canadian Cancer Trials Group partner on three pan-Canadian projects aimed at making immunotherapy more effective for cancer patients
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand ... -
New hope for pancreatic cancer treatments [EXTERNAL MEDIA]
(Globe and Mail, June 21, 2024) Marathon of Hope Cancer Centres Network supports clinical trial to increase personalized treatment based on an individual’s cancer genetics -
New pan-Canadian project aims to discover if personalized lifestyle interventions can help improve the efficacy of prostate cancer treatments
A pan-Canadian team of researchers and clinicians will seek to better understand if lifestyle interventions can help improve the efficacy of prostate cancer treatments thanks to new funding from the M...
Projects
-
Neoadjuvant precision therapy for non-small cell lung cancer: A platform for discovery
Tracking immunotherapy response to personalize treatment for lung cancer patients -
Canadian Head And Neck cancer GEnomic (CHANGE) Collaborative
Understanding the molecular underpinnings of high recurrence rates in oral squamous cell carcinoma to improve survival and quality of life for patients -
Canadian framework to improve predictive models for immunotherapy interventions (CAN-PREDICT-IT)
Developing multi-modal biomarkers to predict response to specific immunotherapies